ESR1 and colorectal carcinoma: Four compounds (11-O-galloylbergenin, 11-O-protocatechuoylbergenin, 11-O-syringylbergenin, epicatechin-3-gallate) had a lower docking score than the ligand-protein of SRC, and two compounds (bergenin, epicatechin-3-gallate) docked better than the ligand-protein of ESR1 (Table 1), which indicated that AGS had multiple ingredients and multiple targets against CRC.